Q-omics provides the consensus-scored LINC00330 profile across patient tissues and cancer cell-line models. LINC00330 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC00330 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, LINC00330 RNA expression shows 6,625 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, HNSC, and TGCT as cancer lineages where LINC00330 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00330 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00330 survival associations across molecular data types. LINC00330 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00330 RNA expression–survival associations across cancer types. High LINC00330 expression shows unfavorable associations in KIRC, SKCM, MESO, BRCA, SARC and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC00330 RNA expression.
This table summarizes LINC00330 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00330. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00330 shows lower tumor expression in HNSC, KIRC, KIRP, THCA and STAD and higher tumor expression in LUAD. The HNSC box plot shows higher LINC00330 RNA expression in normal versus tumor tissue (log2 FC = −1.687, t-test p < 0.001).
This table shows molecular features associated with LINC00330 in patient tissues and cancer cell lines. In patient samples, LINC00330 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
